Mga Batayang Estadistika
| CIK | 1805890 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Fusion Pharmaceuticals Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-39344 Fusion Pharmaceuticals Inc. (Exact name of registrant as specified |
|
| June 4, 2024 |
As filed with the Securities and Exchange Commission on June 4, 2024 As filed with the Securities and Exchange Commission on June 4, 2024 No. 333-239568 No. 333-254687 No. 333-263631 No. 333-270597 No. 333-278106 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to: FORM S-8 REGISTRATION STATEMENT No. 333-239568 FORM S-8 REGISTRATION STATEMENT No. 333-254687 FORM S-8 REGISTRATION STATEMENT No. 333-263631 FORM S-8 |
|
| June 4, 2024 |
As filed with the Securities and Exchange Commission on June 4, 2024 POS AM As filed with the Securities and Exchange Commission on June 4, 2024 No. 333-257653 No. 333-270604 No. 333-272713 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to: FORM S-3 REGISTRATION STATEMENT No. 333-257653 FORM S-3 REGISTRATION STATEMENT No. 333-270604 FORM S-3 REGISTRATION STATEMENT No. 333-272713 UNDER THE SECURITIES ACT OF 193 |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 4, 2024 |
Acquisition of Fusion Pharmaceuticals Completed Exhibit 99.1 Acquisition of Fusion Pharmaceuticals Completed HAMILTON, ON and BOSTON, June 4, 2024 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), announced the successful completion of the acquisition of all of the issued and outstanding shares of Fusion by a wholly-owned subsidiary of AstraZ |
|
| June 4, 2024 |
As filed with the Securities and Exchange Commission on June 4, 2024 As filed with the Securities and Exchange Commission on June 4, 2024 No. 333-239568 No. 333-254687 No. 333-263631 No. 333-270597 No. 333-278106 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to: FORM S-8 REGISTRATION STATEMENT No. 333-239568 FORM S-8 REGISTRATION STATEMENT No. 333-254687 FORM S-8 REGISTRATION STATEMENT No. 333-263631 FORM S-8 |
|
| June 4, 2024 |
As filed with the Securities and Exchange Commission on June 4, 2024 As filed with the Securities and Exchange Commission on June 4, 2024 No. 333-239568 No. 333-254687 No. 333-263631 No. 333-270597 No. 333-278106 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to: FORM S-8 REGISTRATION STATEMENT No. 333-239568 FORM S-8 REGISTRATION STATEMENT No. 333-254687 FORM S-8 REGISTRATION STATEMENT No. 333-263631 FORM S-8 |
|
| June 4, 2024 |
As filed with the Securities and Exchange Commission on June 4, 2024 As filed with the Securities and Exchange Commission on June 4, 2024 No. 333-239568 No. 333-254687 No. 333-263631 No. 333-270597 No. 333-278106 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to: FORM S-8 REGISTRATION STATEMENT No. 333-239568 FORM S-8 REGISTRATION STATEMENT No. 333-254687 FORM S-8 REGISTRATION STATEMENT No. 333-263631 FORM S-8 |
|
| June 4, 2024 |
As filed with the Securities and Exchange Commission on June 4, 2024 As filed with the Securities and Exchange Commission on June 4, 2024 No. 333-239568 No. 333-254687 No. 333-263631 No. 333-270597 No. 333-278106 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to: FORM S-8 REGISTRATION STATEMENT No. 333-239568 FORM S-8 REGISTRATION STATEMENT No. 333-254687 FORM S-8 REGISTRATION STATEMENT No. 333-263631 FORM S-8 |
|
| June 4, 2024 |
As filed with the Securities and Exchange Commission on June 4, 2024 POS AM As filed with the Securities and Exchange Commission on June 4, 2024 No. 333-257653 No. 333-270604 No. 333-272713 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to: FORM S-3 REGISTRATION STATEMENT No. 333-257653 FORM S-3 REGISTRATION STATEMENT No. 333-270604 FORM S-3 REGISTRATION STATEMENT No. 333-272713 UNDER THE SECURITIES ACT OF 193 |
|
| June 4, 2024 |
As filed with the Securities and Exchange Commission on June 4, 2024 As filed with the Securities and Exchange Commission on June 4, 2024 No. 333-257653 No. 333-270604 No. 333-272713 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to: FORM S-3 REGISTRATION STATEMENT No. 333-257653 FORM S-3 REGISTRATION STATEMENT No. 333-270604 FORM S-3 REGISTRATION STATEMENT No. 333-272713 UNDER THE SECURITIES ACT OF 1933 Fusio |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 31, 2024 |
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement Exhibit 99.1 Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement HAMILTON, ON and BOSTON, May 31, 2024 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced it has obtained a final order from the Ontario Superior Court of Justice (Commercial |
|
| May 29, 2024 |
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca Exhibit 99.1 Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca HAMILTON, ON and BOSTON, May 29, 2024 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced that at a special meeting of its shareholders (the “Shareholders”), held virtually ea |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) ☐ Defini |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 7, 2024 |
Exhibit 99.1 Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates Presented interim data from TATCIST trial of FPI-2265 in mCRPC at the 2024 American Association for Cancer Research (AACR) Annual Meeting Signed definitive agreement to be acquired by AstraZeneca for total transaction value of up to $2.4 billion; transaction expected to close in |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39344 Fusion Pharmaceuticals Inc. |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| April 25, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3 |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2024 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of Incorporation) (Comm |
|
| April 10, 2024 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Fusion Pharmaceuticals Inc. |
|
| April 10, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2024 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 8, 2024 |
Fusion Networks Holdings, Inc. / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 form1745fusion.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3*) FUSION PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36118A100 (CUSIP Number) March 31, 2024 (Date of E |
|
| March 25, 2024 |
Fusion Networks Holdings, Inc. / FEDERATED HERMES, INC. Activist Investment SC 13D 1 form.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* FUSION PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36118A100 (CUSIP Number) STEPHEN VAN METER, CHIEF COMPLIANCE OFFICER FEDERATED HERMES, INC. FEDERATED HERMES TOWER 1001 LIBERTY AVENUE PITTSBURGH, |
|
| March 20, 2024 |
Exhibit 99.1 Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates Company recently announced definitive agreement to be acquired by AstraZeneca FPI-2265 Phase 2/3 registrational program for patients with metastatic castration-resistant prostate cancer (mCRPC) expected to begin in Q2 2024 Interim data from TATCIST study of FPI-226 |
|
| March 20, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Fusion Pharmaceuticals Inc. |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39344 Fusion Pharmace |
|
| March 20, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 20, 2024 |
Employment Agreement between the Company and Eric Burak, Ph.D. (dated as of December 18, 2023) Exhibit 10.10 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Fusion Pharmaceuticals Inc. (the “Company”), and Eric Burak (the “Executive”) and is effective as of December 18, 2023 (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agree |
|
| March 20, 2024 |
EX-99.5 2 d805091dex995.htm EX-99.5 Exhibit 5 Execution Version VOTING AND SUPPORT AGREEMENT THIS VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of March 18, 2024, by and between AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden, having its official seat in Södertälje, Sweden, its registered office address at 151 |
|
| March 20, 2024 |
Amended and Restated General By-Laws of the Company Exhibit 3.2 AMENDED AND RESTATED GENERAL BY-LAWS OF FUSION PHARMACEUTICALS INC. (the “Corporation”) TABLE OF CONTENTS Page 1 - DEFINITIONS 1 1.1 Definitions 1 1.2 Interpretation 1 1.3 Execution in Counterpart, by Facsimile and by Electronic Signature 1 2 - GENERAL BUSINESS 2 2.1 Registered Office 2 2.2 Seal 2 2.3 Fiscal Year 2 2.4 Execution of Instruments 2 2.5 Banking Arrangements 2 2.6 Voting Ri |
|
| March 20, 2024 |
As filed with the Securities and Exchange Commission on March 20, 2024 As filed with the Securities and Exchange Commission on March 20, 2024 Registration No. |
|
| March 20, 2024 |
Fusion Networks Holdings, Inc. / HealthCap VII, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3) Fusion Pharmaceuticals Inc. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 36118A100 (CUSIP Number) HealthCap VII, L.P. Represented by HealthCap VI GP S.A. 23 Avenue Villamont Lausanne, Switzerland CH-1005 |
|
| March 20, 2024 |
Exhibit 19.1 FUSION PHARMACEUTICALS INC. Statement of Company POLICY on INSIDER TRADING AND DISCLOSURE, AMENDED This memorandum sets forth the policy of Fusion Pharmaceuticals Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Insider Trading Policy (the “Insider Tra |
|
| March 20, 2024 |
Exhibit 97.1 Fusion PHARMACEUTICALS Inc. COMPENSATION RECOVERY POLICY Adopted as of June 14, 2023 Fusion Pharmaceuticals Inc. (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from current and former Executive Office |
|
| March 20, 2024 |
Exhibit 21.1 FUSION PHARMACEUTICALS INC. The following is a list of significant subsidiaries of Fusion Pharmaceuticals Inc. as of December 31, 2023. SUBSIDIARY STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Fusion Pharmaceuticals US Inc. Delaware |
|
| March 19, 2024 |
EX-99.1 Exhibit 99.1 CONFIDENTIAL Agreed Form VOTING AND SUPPORT AGREEMENT THIS VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of March 18, 2024, by and between AstraZeneca AB, a public company with limited liability (Aktiebolag), incorporated under the laws of Sweden (“Parent”), and the undersigned holder (the “Shareholder”) of common shares of Fusion Pharmaceuticals |
|
| March 19, 2024 |
EX-10.1 Exhibit 10.1 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment (the “Amendment”) to that certain Employment Agreement, dated as of December 18, 2023 (“Agreement”) is made between Fusion Pharmaceuticals Inc. (the “Company”), and Eric Burak (the “Executive”) and is effective as of March 18, 2024 (the “Effective Date”). WHEREAS, the Company and the Executive entered into the Agreement and now |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant x Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| March 19, 2024 |
EX-99.2 Exhibit 99.2 Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer Transaction includes actinium-based clinical-stage radioconjugate targeting PSMA for prostate cancer, pipeline of radioconjugates and state-of-the-art R&D and manufacturing facilities Fusion shareholders to receive $21.00 per share in cash at closin |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| March 19, 2024 |
Amendment No. 1 to the General By-laws of Fusion Pharmaceuticals Inc. EX-3.1 Exhibit 3.1 AMENDMENT NO. 1 TO THE GENERAL BY-LAWS OF FUSION PHARMACEUTICALS INC. (the “Corporation”) WHEREAS, the board of directors (the “Board”) of the Corporation has determined that it is advisable and in the best interests of the Corporation to amend the General By-laws of the Corporation (the “Bylaws”) to change the sole and exclusive forum for resolving any complaint filed in the Un |
|
| March 19, 2024 |
EX-99.3 Exhibit 99.3 Dear Fusionites: Today is an important day in Fusion’s trajectory. A few minutes ago, we announced that our company has entered into a definitive agreement with AstraZeneca, pursuant to which, AstraZeneca will acquire all of our company’s outstanding shares for a price of $21.00 per share in cash, plus a non-transferrable contingent value right (CVR) for $3.00 per share in cas |
|
| March 19, 2024 |
EX-2.1 [***] Indicates that certain information in this exhibit has been excluded because it is both (i) not material and (ii) is the type that the registrant customarily and actually treats as private or confidential. Exhibit 2.1 Execution Version ASTRAZENECA AB — and — 15863210 CANADA INC. — and — FUSION PHARMACEUTICALS INC. ARRANGEMENT AGREEMENT March 18, 2024 Execution Version TABLE OF CONTENT |
|
| March 7, 2024 |
Fusion Networks Holdings, Inc. / HealthCap VII, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2) Fusion Pharmaceuticals Inc. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 36118A100 (CUSIP Number) HealthCap VII, L.P. Represented by HealthCap VI GP S.A. 23 Avenue Villamont Lausanne, Switzerland CH-1005 |
|
| March 7, 2024 |
EX-99.4 2 d750423dex994.htm EX-99.4 Exhibit 4 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing this statement on Schedule 13D jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of th |
|
| February 16, 2024 |
Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. LICENSE AGREEMENT This License Agreement (“Agreement”), made as of 16 February 2024 (“Effective Date”), is by and among Fusion |
|
| February 16, 2024 |
Exhibit 99.1 Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy FPI-2265 positioned to be the first approved PSMA targeted alpha therapy Hamilton, ON & Boston, MA, Feb. 16, 2024 – Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generati |
|
| February 16, 2024 |
Regulation FD Disclosure, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2024 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Co |
|
| February 14, 2024 |
Fusion Networks Holdings, Inc. / CANADA PENSION PLAN INVESTMENT BOARD - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) FUSION PHARMACEUTICALS INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 36118A100 (CUSIP Number |
|
| February 13, 2024 |
Fusion Networks Holdings, Inc. / Avidity Partners Management LP Passive Investment SC 13G/A 1 d1097887213g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Fusion Pharmaceuticals, Inc. (Name of Issuer) Common shares, no par value per share (Title of Class of Securities) 36118A100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| January 19, 2024 |
Fusion Networks Holdings, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Fusion Pharmaceuticals Inc. (Name of Issuer) Common shares, no par value per share (Title of Class of Securities) 36118A100 (CUSIP Number) January 9, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| January 19, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2024 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Com |
|
| January 19, 2024 |
Up to $100,000,000 Common Shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257653 PROSPECTUS SUPPLEMENT (To Prospectus dated July 13, 2021) Up to $100,000,000 Common Shares We have entered into an amendment, dated January 19, 2024, or the Amendment, to the Open Market Sales AgreementSM, or, as amended by the Amendment, the Sales Agreement, with Jefferies LLC, or Jefferies, acting as our sales agent, |
|
| January 19, 2024 |
EX-1.1 Exhibit 1.1 AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSM January 19, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 1 to the Open Market Sale AgreementSM (this “Amendment No. 1”) is entered into as of the date first written above by and between Fusion Pharmaceuticals Inc., a corporation existing under the Canada Business Corpor |
|
| January 19, 2024 |
EX-99.1 2 d689626dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: January 19, 20 |
|
| January 18, 2024 |
Fusion Networks Holdings, Inc. / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 fusn1569-form.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2*) FUSION PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36118A100 (CUSIP Number) December 31, 2023 (Date of |
|
| January 4, 2024 |
Corporate Presentation January 2024 Copyright © 2024 Fusion Pharmaceuticals Inc. All Rights Reserved Exhibit 99.2 Forward-Looking Statements This presentation contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements that are based on our management's belief and assumptions and on information |
|
| January 4, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Comm |
|
| January 4, 2024 |
Exhibit 99.1 Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates - Aligned with the FDA on submitted protocol for 225Ac-PSMA (FPI-2265) Phase 2/3 registrational program for patients with metastatic castration-resistant prostate cancer (mCRPC) - Achieved target enrollment in ongoing TATCIST trial evaluating FPI-2265; Interim Phase 2 data expected to be presented in April 202 |
|
| December 18, 2023 |
Fusion Networks Holdings, Inc. / Flynn James E Passive Investment SC 13G 1 e619129sc13g-fp.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) * Fusion Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36118A100 (CUSIP Number) December 14, |
|
| November 7, 2023 |
Exhibit 99.1 Fusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program Updates Preliminary data for FPI-2265 (225Ac-PSMA I&T) in approximately 20 to 30 patients on track for Q1 2024 Data from Cohort 2 of the FPI-1434 Phase 1 study anticipated around year-end 2023 FPI-2068, a bispecific IgG-based targeted alpha therapy for solid tumors that co-express EGFR-cMET, dev |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of Incorporation) (Com |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39344 Fusion Pharmaceuticals Inc. |
|
| October 23, 2023 |
Fusion Networks Holdings, Inc. / Avidity Partners Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 16, 2023 |
Exhibit 99.1 Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors Hamilton, ON & Boston, MA, October 16, 2023 – Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced the appointment of Jeremy Bender, Ph. |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of Incorporation) (Com |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 8, 2023 |
Exhibit 99.1 Fusion Pharmaceuticals Announces Second Quarter 2023 Financial Results and Clinical Program Updates FPI-2265 (Ac-PSMA I&T) IND transferred to Fusion; program is enrolling patients and on track for Q1 2024 update Preliminary clinical data presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) from the Phase 1 Trial of FPI-1434 showed the cold/hot dosing regimen demo |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39344 Fusion Pharmaceuticals Inc. |
|
| June 27, 2023 |
EX-99.1 Exhibit 99.1 Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R Preliminary Clinical Data with Cold/Hot Dosing Regimen Demonstrate Potential to Improve Therapeutic Index and Safety Profile Company Prioritizing Cold/Hot Dosing Regimen in Phase 1 Trial; Cohort 2 in this Arm is Currently Enrolling Data to be Presented |
|
| June 27, 2023 |
EX-99.2 Exhibit 99.2 FPI-1434 Phase 1 Data Update June 27, 2023 Copyright © 2020 Fusion Pharma Inc. All Rights Reserved Forward-Looking Statements and Legal Disclaimers This presentation contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements that are based on our management's belief and ass |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| June 23, 2023 |
FUSION PHARMACEUTICALS INC. 270 Longwood Road South Hamilton, Ontario, Canada, L8P 0A6 CORRESP FUSION PHARMACEUTICALS INC. 270 Longwood Road South Hamilton, Ontario, Canada, L8P 0A6 June 23, 2023 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Fusion Pharmaceuticals Inc.: Registration Statement on Form S-3 filed June 16, 2023 (File No. 333-272713) Ladies and Gentlemen: Pursuant to R |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| June 16, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Fusion Pharmaceuticals Inc. |
|
| June 16, 2023 |
As filed with the Securities and Exchange Commission on June 16, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on June 16, 2023 Registration No. |
|
| June 9, 2023 |
Fusion Networks Holdings, Inc. / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1*) FUSION PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36118A100 (CUSIP Number) May 31, 2023 (Date of Event Which Requires Filing of th |
|
| May 16, 2023 |
Fusion Networks Holdings, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Fusion Pharmaceuticals Inc. (Name of Issuer) COMMON SHARES (Title of Class of Securities) 36118A100 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 73 |
|
| May 16, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 2 to the Statement on Schedule 13D, dated May 11, 2023, with respect to the common shares of Fusion Pharmaceuticals Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be respon |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39344 Fusion Pharmaceuticals Inc. |
|
| May 11, 2023 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 10, 2023 by and among Fusion Pharmaceuticals Inc., a corporation existing under the Canada Business Corporations Act (the “Company”), and the investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS A. T |
|
| May 11, 2023 |
EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of May 10, 2023 by and among Fusion Pharmaceuticals Inc., a corporation existing under the Canada Business Corporations Act (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as o |
|
| May 11, 2023 |
EX-99.1 4 d467856dex991.htm EX-99.1 Exhibit 99.1 Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates FPI-2265 (Ac-PSMA I&T) program enrolling patients and on track for Q1 2024 update Preliminary Phase 1 data for FPI-1434 expected to be reported at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting Clinical progress across TAT |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| May 11, 2023 |
Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entere |
|
| April 27, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 21, 2023 |
FUSION PHARMACEUTICALS INC. 270 Longwood Road South Hamilton, Ontario, Canada, L8P 0A6 FUSION PHARMACEUTICALS INC. 270 Longwood Road South Hamilton, Ontario, Canada, L8P 0A6 March 21, 2023 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Fusion Pharmaceuticals Inc.: Registration Statement on Form S-3 filed March 16, 2023 (File No. 333-270604) Ladies and Gentlemen: Pursuant to Rule 46 |
|
| March 16, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Fusion Pharmaceuticals Inc. |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39344 Fusion Pharmace |
|
| March 16, 2023 |
Exhibit 21.1 FUSION PHARMACEUTICALS INC. The following is a list of significant subsidiaries of Fusion Pharmaceuticals Inc. as of December 31, 2022. SUBSIDIARY STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Fusion Pharmaceuticals US Inc. Delaware |
|
| March 16, 2023 |
Power of Attorney (included on the signature page). Table of Contents As filed with the Securities and Exchange Commission on March 16, 2023 Registration No. |
|
| March 16, 2023 |
Exhibit 4.4 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN |
|
| March 16, 2023 |
As filed with the Securities and Exchange Commission on March 16, 2023 As filed with the Securities and Exchange Commission on March 16, 2023 Registration No. |
|
| March 16, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Fusion Pharmaceuticals Inc. |
|
| March 16, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 16, 2023 |
Exhibit 99.1 Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results and Clinical Program Updates Company recently acquired IND for ongoing Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a small molecule radiopharmaceutical targeting PSMA positive mCRPC FPI-1434 preliminary Phase 1 data expected in Q2 2023 FPI-1966 and FPI-2059 Phase 1 trials open and recruiting patients Strong b |
|
| March 16, 2023 |
Employment Agreement between the Company and Dmitri Bobilev, MD (dated as of November 7, 2022) Exhibit 10.12 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Fusion Pharmaceuticals Inc. (“Parent Company”), Fusion Pharmaceuticals US Inc., a Delaware corporation and US subsidiary of the Parent Company (the “Company”), and Dmitri Bobilev (the “Executive”) and is effective as of November 7, 2022, or such other date as may be agreed upon by the parties based on the ti |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 6, 2023 |
Fusion Networks Holdings, Inc. / HealthCap VII, L.P. - SC 13D/A Activist Investment SC 13D/A Schedule 13D Page 1 of 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 28, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated February 16, 2023, with respect to the common shares of Fusion Pharmaceuticals Inc. |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1)* Under the Securities Exchange Act of 1934 Fusion Pharmaceuticals Inc. (Name of Issuer) COMMON SHARES (Title of Class of Securities) 36118A100 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 73 |
|
| February 14, 2023 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of February 13, 2023 by and among Fusion Pharmaceuticals Inc., a corporation existing under the Canada Business Corporations Act (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of F |
|
| February 14, 2023 |
Exhibit 99.1 Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer Acquisition of Phase 2 program with established clinical proof of concept strengthens pipeline of innovative targeted alpha therapies In connection with the transaction, Fusion announces $60.0 million private placement financing Fusion to |
|
| February 14, 2023 |
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T Copyright © 2023 Fusion Pharmaceuticals Inc. |
|
| February 14, 2023 |
Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. OPTION AND ASSET PURCHASE AGREEMENT dated as of November 14, 2022 by and between RADIOMEDIX, INC. and FUSION PHARMACEUTICALS IN |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2023 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction o |
|
| February 14, 2023 |
Exhibit 99.3 As used in this Exhibit 99.3, unless the context indicates otherwise, references to “Fusion,” “the Company,” “we,” “us,” “our” and similar references refer to Fusion Pharmaceuticals, Inc. and its wholly owned subsidiaries. Risks associated with the in-licensing or acquisition of drug candidates could cause substantial delays in the preclinical and clinical development of our drug cand |
|
| February 14, 2023 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of February 13, 2023 by and among Fusion Pharmaceuticals Inc., a corporation existing under the Canada Business Corporations Act (the “Company”), and the investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS A. The |
|
| February 13, 2023 |
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T Copyright © 2023 Fusion Pharmaceuticals Inc. |
|
| February 13, 2023 |
Exhibit 99.3 As used in this Exhibit 99.3, unless the context indicates otherwise, references to “Fusion,” “the Company,” “we,” “us,” “our” and similar references refer to Fusion Pharmaceuticals, Inc. and its wholly owned subsidiaries. Risks associated with the in-licensing or acquisition of drug candidates could cause substantial delays in the preclinical and clinical development of our drug cand |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2023 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Co |
|
| February 13, 2023 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of February 13, 2023 by and among Fusion Pharmaceuticals Inc., a corporation existing under the Canada Business Corporations Act (the “Company”), and the investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS A. The |
|
| February 13, 2023 |
Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. OPTION AND ASSET PURCHASE AGREEMENT dated as of November 14, 2022 by and between RADIOMEDIX, INC. and FUSION PHARMACEUTICALS IN |
|
| February 13, 2023 |
Exhibit 99.1 Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer Acquisition of Phase 2 program with established clinical proof of concept strengthens pipeline of innovative targeted alpha therapies In connection with the transaction, Fusion announces $60.0 million private placement financing Fusion to |
|
| February 13, 2023 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of February 13, 2023 by and among Fusion Pharmaceuticals Inc., a corporation existing under the Canada Business Corporations Act (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of F |
|
| February 1, 2023 |
Fusion Networks Holdings, Inc. / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. *) FUSION PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36118A100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing o |
|
| January 27, 2023 |
Fusion Networks Holdings, Inc. / JOHNSON & JOHNSON - SCHEDULE 13G/A Passive Investment SC 13G/A 1 s13ga123122-fusion.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1 )1 Fusion Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) |
|
| November 8, 2022 |
EX-10.2 3 fusn-ex102.htm EX-10.2 EXHIBIT 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY A |
|
| November 8, 2022 |
Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CONSENT AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS CONSENT AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (t |
|
| November 8, 2022 |
Exhibit 99.1 Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Results and Clinical Program Updates FPI-1434 Phase 1 data on track to be reported in first half of 2023 Phase 1/2 Study of FPI-1966 open and enrolling patients with solid tumors expressing FGFR3 Strong balance sheet with $205.5 million in cash, cash equivalents and investments with runway into Q3 2024 Hamilton, ON & Boston |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2022 Fusion Pharmaceuticals Inc. (Exact name of Registrant as Specified in Its Charter) Canada 001-39344 Not applicable (State or Other Jurisdiction of Incorporation) (Co |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39344 Fusion Pharmaceuticals Inc. |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39344 Fusion Pharmaceuticals Inc. |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| August 9, 2022 |
Exhibit 99.1 Fusion Pharmaceuticals Announces Second Quarter 2022 Financial Results and Clinical Program Updates FPI-2059 IND cleared by FDA; Clinical portfolio expanded to include small molecule- based targeted alpha therapy Data supporting ongoing evaluation of cold antibody pre-administration dosing regimen in Phase 1 study of FPI-1434 presented at SNMMI 2022 Annual Meeting Company strengthens |
|
| August 9, 2022 |
Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemen |
|
| June 21, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| June 9, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| June 9, 2022 |
Fusion Pharmaceuticals Provides Updates on FPI-1434 and FPI-1966 Clinical Programs EX-99.1 2 d281599dex991.htm EX-99.1 Exhibit 99.1 Fusion Pharmaceuticals Provides Updates on FPI-1434 and FPI-1966 Clinical Programs Hamilton, ON & Boston, MA, June 9, 2022 – Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced updates on its Phase 1 clinical trial evaluating |
|
| June 9, 2022 |
Corporate Presentation June 2022 Copyright ? 2021 Fusion Pharmaceuticals Inc. All Rights Reserved Exhibit 99.2 Forward-Looking Statements and Legal Disclaimers This presentation contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements that are based on our management's belief and assumptions |
|
| May 10, 2022 |
EX-99.1 2 d359189dex991.htm EX-99.1 Exhibit 99.1 Fusion Pharmaceuticals Announces First Quarter 2022 Financial Results and Clinical Program Updates Phase 1 data for FPI-1434 anticipated to be reported in the second half of 2022 Company continues to build a diversified pipeline of TATs and advance manufacturing and actinium supply chain capabilities Hamilton, ON & Boston, MA, May 10, 2022 – Fusion |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39344 Fusion Pharmaceuticals Inc. |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| April 29, 2022 |
DEFA14A 1 d237826ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Prox |
|
| April 29, 2022 |
DEF 14A 1 d237826ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| March 17, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Fusion Pharmaceuticals Inc. |
|
| March 17, 2022 |
As filed with the Securities and Exchange Commission on March 17, 2022 As filed with the Securities and Exchange Commission on March 17, 2022 Registration No. |
|
| March 17, 2022 |
Exhibit 10.14 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made between Fusion Pharmaceuticals Inc. (?Parent Company?), Fusion Pharmaceuticals US, Inc., a Delaware corporation and US subsidiary of the Parent Company (the ?Company?), and Chris Leamon (the ?Executive?) and is effective as of November 1, 2021, or such other date as may be agreed upon by the parties based on the tim |
|
| March 17, 2022 |
Exhibit 99.1 Fusion Pharmaceuticals Announces Fourth Quarter 2021 Financial Results and Clinical Program Updates - Company is advancing first targeted alpha therapy (TAT) candidate under collaboration with AstraZeneca - Recently signed research collaborations support expansion of pipeline into peptide-based radiopharmaceuticals - Company continues to build a diversified pipeline of TATs and advanc |
|
| March 17, 2022 |
Exhibit 10.13 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made between Fusion Pharmaceuticals Inc. (?Parent Company?), Fusion Pharmaceuticals US, Inc., a Delaware corporation and US subsidiary of the Parent Company (the ?Company?), and Mohit Rawat (the ?Executive?) and is effective as of September 27, 2021 (the ?Effective Date?). WHEREAS, the Company desires to employ the Execu |
|
| March 17, 2022 |
Exhibit 21.1 FUSION PHARMACEUTICALS INC. The following is a list of significant subsidiaries of Fusion Pharmaceuticals Inc. as of December 31, 2021. SUBSIDIARY STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Fusion Pharmaceuticals US Inc. Delaware |
|
| March 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39344 Fusion Pharmace |
|
| February 14, 2022 |
Fusion Networks Holdings, Inc. / ADAMS STREET PARTNERS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm226194d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Fusion Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36118A100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| January 18, 2022 |
Fusion Networks Holdings, Inc. / TPG GP A, LLC - AMENDED SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Fusion Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 36118A100 (CUSIP Number) Bradford Berenson TPG Inc. 301 Commerce Street, Suite 3300 Fort Worth, TX 76102 (817) 871-4000 (Name, Address and T |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39344 Fusion Pharmaceuticals Inc. |
|
| November 9, 2021 |
Exhibit 10.1 Execution Copy [***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. COLLABORATION AGREEMENT This Collaboration Agreement (this ?Agreement?) is made as of December 10, 2020 (the ?Effective Date?), by and between, on the one hand, Fusion Pharmaceuticals, Inc. |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Com |
|
| November 9, 2021 |
Exhibit 10.4 Execution Copy [***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. Amendment. No. 3 to COLLABORATION AGREEMENT This Amendment No. 3 , (this ?Amendment?) dated as of August 12, 2021 (the ?Effective Date?), to that certain Collaboration Agreement, dated as o |
|
| November 9, 2021 |
Exhibit 10.3 Execution Copy [***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. Amendment. No. 2 to COLLABORATION AGREEMENT This Amendment No. 2 , (this ?Amendment?) dated as of July 27, 2021 (the ?Effective Date?), to that certain Collaboration Agreement, dated as of |
|
| November 9, 2021 |
Exhibit 10.2 Execution Copy [***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. Amendment. No. 1 to COLLABORATION AGREEMENT This Amendment No. 1 , (this ?Amendment?) dated as of June 28, 2021 (the ?Effective Date?), to that certain Collaboration Agreement, dated as of |
|
| November 9, 2021 |
Exhibit 99.1 Fusion Pharmaceuticals Announces Third Quarter 2021 Financial Results and Clinical Program Update FPI-1434 Phase 1 multi-dose data now expected in 2H 2022 FPI-1966 Phase 1 study initiated; first patient expected to be dosed in Q1 2022 FPI-2059 investigational new drug application (IND) on track for first half 2022 Hamilton, ON & Boston, MA, November 9, 2021 ? Fusion Pharmaceuticals In |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Comm |
|
| August 13, 2021 |
Exhibit 99.1 Fusion Pharmaceuticals and TRIUMF Announce Expanded R&D Collaboration for Actinium Supply Production Fusion and TRIUMF to collaborate to produce actinium based on technology developed by TRIUMF Hamilton, ON, Boston, MA, and Vancouver, BC, August 12, 2021 ? Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceu |
|
| August 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Comm |
|
| August 10, 2021 |
EX-99.1 2 d179356dex991.htm EX-99.1 Exhibit 99.1 Fusion Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Update Phase 1 study of FPI-1434 progressing towards multi-dose data and recommended Phase 2 dose in 1H2022 FPI-1966 advancing to clinic Hamilton, ON & Boston, MA, August 10, 2021 – Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39344 Fusion Pharmaceuticals Inc. |
|
| July 23, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2021 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Comm |
|
| July 8, 2021 |
FUSION PHARMACEUTICALS INC. 270 Longwood Road South Hamilton, Ontario, Canada, L8P 0A6 FUSION PHARMACEUTICALS INC. 270 Longwood Road South Hamilton, Ontario, Canada, L8P 0A6 July 8, 2021 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Fusion Pharmaceuticals Inc.: Registration Statement on Form S-3 filed July 2, 2021 (File No. 333-257653) Ladies and Gentlemen: Pursuant to Rule 461 un |
|
| July 2, 2021 |
Form of Subordinated Indenture Exhibit 4.3 FUSION PHARMACEUTICALS INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?] Subordinated Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certi |
|
| July 2, 2021 |
Consent of Goodwin Procter LLP (included in Exhibit 5.3) EX-5.3 Exhibit 5.3 July 2, 2021 Fusion Pharmaceuticals Inc. 270 Longwood Rd., S. Hamilton, Ontario Canada Re: Securities Being Registered under Registration Statement on Form S-3 We have acted as U.S. counsel to you in connection with your filing of a Registration Statement on Form S-3 (as amended or supplemented, the “Registration Statement”) pursuant to the Securities Act of 1933, as amended (th |
|
| July 2, 2021 |
Exhibit 4.2 FUSION PHARMACEUTICALS INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?] Senior Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate |
|
| July 2, 2021 |
As filed with the Securities and Exchange Commission on July 2, 2021 Table of Contents As filed with the Securities and Exchange Commission on July 2, 2021 Registration No. |
|
| July 2, 2021 |
Sales Agreement, dated July 2, 2021, by and between the Registrant and Jefferies LLC EX-1.2 2 d15840dex12.htm EX-1.2 Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM July 2, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Fusion Pharmaceuticals Inc., a corporation existing under the Canada Business Corporations Act (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as |
|
| July 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2021 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| June 7, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2021 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| June 3, 2021 |
Fusion Pharmaceuticals Enters into Agreement to Build Radiopharmaceutical Manufacturing Facility Exhibit 99.1 Fusion Pharmaceuticals Enters into Agreement to Build Radiopharmaceutical Manufacturing Facility Hamilton, ON & Boston, MA, May XX, 2021 ? Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it entered a 15-year lease agreement with Hamilton, Ontario-based McMas |
|
| June 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Commiss |
|
| June 3, 2021 |
Exhibit 10.1 1 LEASE AGREEMENT Between McMASTER UNIVERSITY (the ?Landlord?) ?and? FUSION PHARMACEUTICALS INC., A body corporate incorporated under the laws of the Province of Ontario (the ?Tenant?) Part of 270 Longwood Road South, Hamilton 2 TABLE OF CONTENTS ARTICLE 1 ? DEFINITIONS 5 ARTICLE 2 ? TERM AND USE 10 ARTICLE 3 ? RENT 17 ARTICLE 4 ? MAINTENANCE, REPAIRS AND ALTERATIONS 21 ARTICLE 5 ? LA |
|
| May 11, 2021 |
10-Q 1 fusn-10q20210331.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission F |
|
| May 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d77252d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of |
|
| May 11, 2021 |
Exhibit 99.1 Fusion Pharmaceuticals Announces First Quarter 2021 Financial Results and Business Update Phase 1 study of FPI-1434 Phase 1 enrollment continues on track for data in 1H2022 Continuing expansion of pipeline of targeted alpha therapies through recently completed transactions Hamilton, ON & Boston, MA, May 11, 2021 ? Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology c |
|
| April 27, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confid |
|
| April 2, 2021 |
Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors EX-99.1 2 d107487dex991.htm EX-99.1 Exhibit 99.1 Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors Hamilton, ON & Boston, MA, April 1, 2021 – Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines today announced the appointment of Donald A. Bergstrom, M.D., P |
|
| April 2, 2021 |
EX-99.1 2 d159237dex991.htm EX-99.1 Exhibit 99.1 Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen Hamilton, ON & Boston, MA, April 1, 2021 – Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it has completed |
|
| April 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2021 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| April 2, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events 8-K 1 d159237d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2021 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction |
|
| March 25, 2021 |
EX-10.8 3 fusn-ex108898.htm EX-10.8 Exhibit 10.8 AMENDMENT No. 1 EMPLOYMENT AGREEMENT This Amendment No. 1 (the “Amendment”) to that certain Employment Agreement, dated as of June 25, 2020 (“Agreement”) is made between Fusion Pharmaceuticals Inc. (the “Company”), and John Valliant (the “Executive”) and is effective as of February 19, 2021 (the “Effective Date”). WHEREAS, the Company and the Execut |
|
| March 25, 2021 |
Exhibit 10.22 Execution Copy AMENDMENT NO. 2 TO ASSET PURCHASE AGREEMENT This Amendment No. 2 to Asset Purchase Agreement (this ?Second Amendment?), effective as of February 8, 2021 (the ?Second Amendment Effective Date?), is entered into by and among Fusion Pharmaceuticals, Inc., a Canadian federal corporation with its principal place of business at 270 Longwood Road S., Hamilton, Ontario L8P 0A6 |
|
| March 25, 2021 |
Exhibit 10.11 AMENDMENT No. 1 EMPLOYMENT AGREEMENT This Amendment No. 1 (the ?Amendment?) to that certain Employment Agreement, dated as of June 25, 2020 (?Agreement?) is made between Fusion Pharmaceuticals Inc. (the ?Company?), and Eric Burak (the ?Executive?) and is effective as of February 19, 2021 (the ?Effective Date?). WHEREAS, the Company and the Executive entered into the Agreement and now |
|
| March 25, 2021 |
EX-99.1 2 d115241dex991.htm EX-99.1 Exhibit 99.1 Fusion Pharmaceuticals Announces Fourth Quarter 2020 Financial Results and Business Update - FPI-1434 Phase 1 study is progressing - Recent transactions and partnerships expand Fusion’s pipeline of targeted alpha therapies in development to treat a broad array of tumor types Hamilton, ON & Boston, MA, March 25, 2021 – Fusion Pharmaceuticals Inc. (Na |
|
| March 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39344 Fusion Pharmace |
|
| March 25, 2021 |
EX-4.3 2 fusn-ex43899.htm EX-4.3 Exhibit 4.3 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT General The following description of the capital stock of Fusion Pharmaceuticals Inc. (the “Company”) is intended as a summary only and therefore is not a complete description of the Company’s capital stock. This description is based upon, and is qualified by reference to, the Com |
|
| March 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2021 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Commi |
|
| March 25, 2021 |
Exhibit 10.24 TWO INTERNATIONAL PLACE Boston, Massachusetts FIRST AMENDMENT TO LEASE Fusion Pharmaceuticals US Inc. First Amendment to Lease (the ?Amendment?) dated as of March 16, 2021, between Fort Hill Square 2 Owner LLC, a Delaware limited liability company (?Landlord?), and Fusion Pharmaceuticals US Inc., a Delaware corporation (?Tenant?). Background Reference is made to that certain Office L |
|
| March 25, 2021 |
As filed with the Securities and Exchange Commission on March 25, 2021 Registration No. |
|
| March 2, 2021 |
EX-99.1 3 d623514dex991.htm EX-99.1 Exhibit 99.1 Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen Fusion to Leverage its Targeted Alpha Therapies (TAT) Expertise to Create FPI-2059, an Alpha-Emitting Radiopharmaceutical Targeting Solid Tumors Hamilton, ON & Boston, MA, March 2, 2021 – Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a |
|
| March 2, 2021 |
EX-10.1 2 d623514dex101.htm EX-10.1 Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. ASSET PURCHASE AGREEMENT dated as of March 1, 2021 by and between IPSEN PHARMA SAS and FUSI |
|
| March 2, 2021 |
EX-99.2 4 d623514dex992.htm EX-99.2 Exhibit 99.2 IPN 1087 Acquisition and Fusion’s Expanding Pipeline March 2021Exhibit 99.2 IPN 1087 Acquisition and Fusion’s Expanding Pipeline March 2021 Fusion – Next Generation TATs for Precision Oncology Targeted Alpha Therapies (TATs) deliver radiation directly to cancer PDAC Imaging cells using a precision medicine approach (theranostics) coronal ■ Fusion ca |
|
| March 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| February 12, 2021 |
Fusion Pharmaceuticals Appoints Philina Lee, Ph.D., to Board of Directors Exhibit 99.1 Fusion Pharmaceuticals Appoints Philina Lee, Ph.D., to Board of Directors Hamilton, ON & Boston, MA, February 11, 2021 ? Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Philina Lee, Ph.D., as a member of the Company?s Board of Directors. D |
|
| February 12, 2021 |
8-K 1 d123441d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2021 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdict |
|
| February 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Fusion Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 36118A100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* FUSION PHARMACEUTICALS INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 36118A100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 4, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) FUSION PHARMACEUTICALS INC. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 36118A100 (CUSIP Number) December 31, 2020 (Date of Event Which Requ |
|
| November 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d715987d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdict |
|
| November 10, 2020 |
EX-99.1 Exhibit 99.1 Fusion Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update - Multi-dosing portion of Fusion’s Phase 1 study of FPI-1434 on track to be initiated in Q4 2020 - Company executes collaboration agreement with AstraZeneca to grow pipeline of next-generation radiopharmaceuticals Hamilton, ON & Boston, MA, November 10, 2020 – Fusion Pharmaceuticals Inc. |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 10-Q 1 fusn-10q20200930.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi |
|
| November 10, 2020 |
Exhibit 10.1 EXECUTION COPY AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT This Amendment No. 1 to Asset Purchase Agreement (this “Amendment”), effective as of October 8, 2020 (the “Amendment Effective Date”), is entered into by and among Fusion Pharmaceuticals, Inc., a Canadian federal corporation with its principal place of business at 270 Longwood Road S., Hamilton, Ontario L8P 0A6 (“Purchaser”); |
|
| November 3, 2020 |
Fusion Pharmaceuticals Appoints Barbara Duncan as Chairperson of the Board of Directors EX-99.1 2 d22908dex991.htm EX-99.1 Exhibit 99.1 Fusion Pharmaceuticals Appoints Barbara Duncan as Chairperson of the Board of Directors Hamilton, ON & Boston, MA, November 2, 2020 – Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Barbara Duncan, former |
|
| November 3, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2020 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) |
|
| November 2, 2020 |
Investor Presentation of Fusion Pharmaceuticals Inc. dated November 2, 2020 EX-99.2 Exhibit 99.2Exhibit 99.2 |
|
| November 2, 2020 |
EX-99.1 3 d98805dex991.htm EX-99.1 Exhibit 99.1 Fusion Pharmaceuticals Announces Collaboration with AstraZeneca to Develop and Commercialize Next-Generation Radiopharmaceuticals and Combination Therapies Collaboration Combines Fusion’s Targeted Alpha Therapies (TATs) Platform with AstraZeneca’s Antibody and Oncology Portfolio to Create Novel Cancer Therapies Fusion to Host a Conference Call at 8:3 |
|
| November 2, 2020 |
EX-10.1 EXHIBIT 10.1 EXECUTION VERSION CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. STRATEGIC COLLABORATION AGREEMENT BETWEEN FUSION PHARMACEUTICALS INC. AND ASTRAZENECA UK LIMITED CONF |
|
| November 2, 2020 |
8-K 1 d98805d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2020 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdictio |
|
| August 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39344 Fusion Pharmaceuticals Inc. |
|
| August 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) ( |
|
| August 11, 2020 |
EX-99.1 Exhibit 99.1 Fusion Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update - Following Fusion’s June 2020 initial public offering, cash runway extended into 2024 Hamilton, ON & Boston, MA, August 11, 2020 – Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medici |
|
| July 23, 2020 |
EXHIBIT 1 Joint Filing Agreement The undersigned hereby agree that they are filing the foregoing statement on Schedule 13G jointly pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. |
|
| July 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Fusion Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 36118A100 (CUSIP Number) June 30, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| July 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Fusion Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 36118A100 (CUSIP Number) Michael LaGatta TPG Global, LLC 301 Commerce Street, Suite 3300 Fort Worth, TX 76102 (817) 871-4000 (Name, Address an |
|
| July 10, 2020 |
Exhibit 1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. |
|
| July 10, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Fusion Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 36118A100 (CUSIP Number) HealthCap VII, L.P. Represented by its general partner HealthCap VII GP S.A. 18 Avenue d?Ouchy Lausanne, V8 CH -1006 +4121 614 3500 (N |
|
| July 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Fusion Pharmaceuticals Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 36118A100 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Addres |
|
| July 7, 2020 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated July 6, 2020, with respect to the ordinary shares of Fusion Pharmaceuticals Inc. |
|
| July 6, 2020 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Fusion Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 36118A100 (CUSIP Number) June 30, 2020 (Date of Eve |
|
| June 30, 2020 |
S-8 1 d929940ds8.htm S-8 As filed with the Securities and Exchange Commission on June 30, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada Not Applicable (State or other jurisdiction of incorpora |
|
| June 30, 2020 |
General By-Laws of the Registrant EX-3.2 Exhibit 3.2 GENERAL BY-LAWS OF FUSION PHARMACEUTICALS INC. (the “Corporation”) TABLE OF CONTENTS 1 - DEFINITIONS 1 1.1 Definitions 1 1.2 Interpretation 1 1.3 Execution in Counterpart, by Facsimile and by Electronic Signature 2 2 - GENERAL BUSINESS 2 2.1 Registered Office 2 2.2 Seal 2 2.3 Fiscal Year 2 2.4 Execution of Instruments 2 2.5 Banking Arrangements 3 2.6 Voting Rights in Other Bodie |
|
| June 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2020 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada 001-39344 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| June 30, 2020 |
Articles of Amendment to the Articles of the Registrant EX-3.1 Exhibit 3.1 SCHEDULE TO ARTICLES OF AMENDMENT OF FUSION PHARMACEUTICALS INC. (the “Corporation”) 1. The Articles of the Corporation be amended as follows: A. Authorized and Issued Capital (a) to create an unlimited number of Common Shares; (a) to create an unlimited number of Preferred Shares, issuable in one or more series; (b) to change each issued and outstanding Non-Voting Common Share |
|
| June 26, 2020 |
12,500,000 Shares Common Shares 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-238968 PROSPECTUS 12,500,000 Shares Common Shares We are offering 12,500,000 common shares. This is our initial public offering of our common shares. Prior to this offering, there has been no public market for our common shares. The initial public offering price is $17.00. Our common shares have been approved for listing |
|
| June 24, 2020 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on June 24, 2020. |
|
| June 23, 2020 |
VIA EDGAR June 23, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attn: Christopher Edwards Joe McCann Re: Fusion Pharmaceuticals Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-238968 Requested Date: June 25, 2020 Requested Time: 4:00 p.m. Eastern Standard Time Dear Mr. Edwards and |
|
| June 23, 2020 |
June 23, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Chris Edwards and Joe McCann Re: Fusion Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-238968 Acceleration Request Requested Date: June 25, 2020 Requested Time: 4:00 p.m., Eastern Standard Time Ladies and Gentlemen: In accordance with Rule 461 |
|
| June 23, 2020 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 FUSION PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Canada Not Applicable (State of incorporation or organization) (I.R.S. Employer Identification No.) 270 Lon |
|
| June 22, 2020 |
Exhibit 10.8 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Fusion Pharmaceuticals Inc. (“Parent Company”), Fusion Pharmaceuticals US, Inc., a Delaware corporation and US subsidiary of the Parent Company (the “Company”), and John Crowley (the “Executive”) and is effective as of the closing of the first underwritten public offering of the equity securities of the Paren |
|
| June 22, 2020 |
Form of Underwriting Agreement EX-1.1 EXHIBIT 1.1 [●] Shares FUSION PHARMACEUTICALS INC. COMMON SHARES UNDERWRITING AGREEMENT [●], 2020 [●], 2020 Morgan Stanley & Co. LLC Jefferies LLC Cowen and Company, LLC As representatives of the several Underwriters c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Cowen and Company, LLC 599 Lexington Avenu |
|
| June 22, 2020 |
EX-10.9 Exhibit 10.9 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Fusion Pharmaceuticals Inc. (the “Company”), and Eric Burak (the “Executive”) and is effective as of the closing of the first underwritten public offering of the equity securities of the Company pursuant to an effective registration statement under the Securities Act of 1933, as amended (United States |
|
| June 22, 2020 |
EX-10.7 Exhibit 10.7 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Fusion Pharmaceuticals Inc. (the “Company”), and John Valliant (the “Executive”) and is effective as of the closing of the first underwritten public offering of the equity securities of the Company pursuant to an effective registration statement under the Securities Act of 1933, as amended (United Sta |
|
| June 22, 2020 |
EX-3.5 Exhibit 3.5 GENERAL BY-LAWS OF FUSION PHARMACEUTICALS INC. (the “Corporation”) TABLE OF CONTENTS 1 - DEFINITIONS 1 1.1 Definitions 1 1.2 Interpretation 1 1.3 Execution in Counterpart, by Facsimile and by Electronic Signature 2 2 - GENERAL BUSINESS 2 2.1 Registered Office 2 2.2 Seal 2 2.3 Fiscal Year 2 2.4 Execution of Instruments 2 2.5 Banking Arrangements 2 2.6 Voting Rights in Other Bodie |
|
| June 22, 2020 |
Table of Contents As filed with the Securities and Exchange Commission on June 22, 2020. |
|
| June 22, 2020 |
EX-10.3 8 d872512dex103.htm EX-10.3 Exhibit 10.3 FUSION PHARMACEUTICALS INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the “Incentive Plan”) is intended to provide an incentive for superior work and to motivate eligible executives of Fusion Pharmaceuticals Inc. (the “Company”) and its subsidiaries toward even higher achievement and busin |
|
| June 22, 2020 |
EX-10.4 Exhibit 10.4 FUSION PHARMACEUTICALS INC. 2020 EMPLOYEE SHARE PURCHASE PLAN The purpose of the Fusion Pharmaceuticals, Inc. 2020 Employee Share Purchase Plan (the “Plan”) is to provide eligible employees of Fusion Pharmaceuticals Inc. (the “Company”) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase common shares of the Company, no par value (the “Comm |
|
| June 22, 2020 |
EX-3.2 Exhibit 3.2 SCHEDULE TO ARTICLES OF AMENDMENT OF FUSION PHARMACEUTICALS INC. (the “Corporation”) 1. The Articles of the Corporation be amended as follows: A. Authorized and Issued Capital (a) to create an unlimited number of Common Shares; (a) to create an unlimited number of Preferred Shares, issuable in one or more series; (b) to change each issued and outstanding Non-Voting Common Share |
|
| June 22, 2020 |
EX-4.2 Exhibit 4.2 The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM - as tenants in common UNIF GIFT MIN ACT - Custodian TEN ENT - as tenants by the entireties (Cust) (Minor) JT TEN - as joint tenants with right of survivorship and not as tenants |
|
| June 22, 2020 |
EX-10.2 Exhibit 10.2 FUSION PHARMACEUTICALS INC. 2020 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Fusion Pharmaceuticals Inc. 2020 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Fusion Pharmaceuticals Inc. (the “Com |
|
| June 22, 2020 |
EX-10.10 Exhibit 10.10 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Fusion Pharmaceuticals Inc. (“Parent Company”), Fusion Pharmaceuticals US, Inc., a Delaware corporation and US subsidiary of the Parent Company (the “Company”), and James O’Leary (the “Executive”) and is effective as of the closing of the first underwritten public offering of the equity securities o |
